These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21484978)

  • 1. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review.
    Chang YH; Chang DM; Lin KC; Shin SJ; Lee YJ
    Diabetes Metab Res Rev; 2011 Sep; 27(6):515-27. PubMed ID: 21484978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
    Mohammadi S; Hosseinzadeh-Attar MJ; Hosseinnezhad A; Hosseini SH; Eshraghian MR; Nezhad MK; Rahmani M; Karimi M
    Diabetes Metab Syndr; 2011; 5(2):71-5. PubMed ID: 22813406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
    Mäestu J; Jürimäe J; Jürimäe T
    Med Sport Sci; 2010; 55():56-68. PubMed ID: 20956860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
    Esteghamati A; Alamdari A; Zandieh A; Elahi S; Khalilzadeh O; Nakhjavani M; Meysamie A
    Diabetes Res Clin Pract; 2011 Feb; 91(2):154-8. PubMed ID: 21122936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
    Nourbakhsh M; Nourbakhsh M; Gholinejad Z; Razzaghy-Azar M
    Scand J Clin Lab Invest; 2015 Apr; 75(2):183-8. PubMed ID: 25723377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma visfatin level in women with polycystic ovary syndrome.
    Dıkmen E; Tarkun I; Cantürk Z; Cetınarslan B
    Gynecol Endocrinol; 2011 Jul; 27(7):475-9. PubMed ID: 20586547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between circulating visfatin and gestational diabetes mellitus: a systematic review and meta-analysis.
    Zhang W; Zhao D; Meng Z; Wang H; Zhao K; Feng X; Li Y; Dun A; Jin X; Hou H
    Acta Diabetol; 2018 Nov; 55(11):1113-1120. PubMed ID: 29992461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visfatin in juvenile obesity - the effect of obesity intervention and sex.
    Krzystek-Korpacka M; Patryn E; Bednarz-Misa I; Hotowy K; Noczynska A
    Eur J Clin Invest; 2011 Dec; 41(12):1284-91. PubMed ID: 21569027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain.
    Martínez Larrad MT; Corbatón Anchuelo A; Fernández Pérez C; Pérez Barba M; Lazcano Redondo Y; Serrano Ríos M;
    PLoS One; 2016; 11(5):e0153976. PubMed ID: 27166797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling.
    Owczarek AJ; Olszanecka-Glinianowicz M; Kocełak P; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Puzianowska-Kuźnicka M; Grodzicki T; Więcek A; Chudek J
    Scand J Clin Lab Invest; 2016 Dec; 76(8):632-640. PubMed ID: 27712122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans.
    Hallschmid M; Randeva H; Tan BK; Kern W; Lehnert H
    Diabetes; 2009 Mar; 58(3):637-40. PubMed ID: 19095760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome.
    Filippatos TD; Derdemezis CS; Kiortsis DN; Tselepis AD; Elisaf MS
    J Endocrinol Invest; 2007 Apr; 30(4):323-6. PubMed ID: 17556870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans.
    Laudes M; Oberhauser F; Schulte DM; Freude S; Bilkovski R; Mauer J; Rappl G; Abken H; Hahn M; Schulz O; Krone W
    Horm Metab Res; 2010 Apr; 42(4):268-73. PubMed ID: 20091460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: a contradictory piece of the puzzle.
    de Luis DA; Sagrado MG; Aller R; Conde R; Izaola O
    Nutrition; 2010; 26(11-12):1130-3. PubMed ID: 19211226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study.
    Baldassarre S; Fragapani S; Panero A; Fedele D; Pinach S; Lucchiari M; Vitale AR; Mengozzi G; Gruden G; Bruno G
    Cardiovasc Diabetol; 2017 Sep; 16(1):119. PubMed ID: 28946871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
    Hetta HF; Ez-Eldeen ME; Mohamed GA; Gaber MA; ElBadre HM; Ahmed EA; Abdellatief RB; Abd-ElBaky RM; Elkady A; Nafee AM; Zahran AM; Ahmad M
    Egypt J Immunol; 2018 Jun; 25(2):141-151. PubMed ID: 30600957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association between both resistin, visfatin and insulin resistance as well as β cell function in the first-degree relatives of type 2 diabetes mellitus].
    Zhang XJ; Wang Z; Li HH; Yu L; Gao S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1393-6. PubMed ID: 21223671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
    Sandeep S; Velmurugan K; Deepa R; Mohan V
    Metabolism; 2007 Apr; 56(4):565-70. PubMed ID: 17379018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
    Alghasham AA; Barakat YA
    Saudi Med J; 2008 Feb; 29(2):185-92. PubMed ID: 18246224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.